Merck drug extends survival in endometrial cancer trial, wins U.S. priority review
Merck's experimental drug, sacituzumab tirumotecan, has received priority review from the FDA after showing significant survival benefits in a late-stage trial for advanced endometrial cancer. The drug targets the TROP2 protein to reduce cancer progression and death risk.
Why it matters
Advancements in targeted cancer therapies offer new hope for patients with limited treatment options and represent a significant milestone for pharmaceutical innovation.
Merck drug extends survival in endometrial cancer trial, wins U.S. priority review left Merck is developing the drug with Chinese biotech Kelun-Biotech, which discovered the therapy |Image used for representational purpose only REUTERS REUTERS https://th-i.thgim.com/public/incoming/46g9ez/article71631480.ece/alternates/FREE_1200/2026-10-22T195840Z_771870664_RC28LDAC1NKN_RTRMADP_3_CANCER-MERCK-MODERNA.JPG Dado Ruvic FILE PHOTO: A vial and syringe are seen in front of Merck logo in this illustration taken March 26, 2025. REUTERS/Dado Ruvic/Illustration/File Photo The drug delivers a cancer-killing payload to cells that carry a protein common in endometrial tumours Oct 26 (Reuters) - The U.S. health regulator has accepted Merck’s experimental targeted drug for a priority review based on data from a late-stage trial where it extended survival in women with an advanced form of endometrial cancer. The drug, sacituzumab tirumotecan, also known as sac-TMT, delivers a cancer-killing payload to cells that carry a protein called TROP2, which is common in endometrial tumors.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in